Vasomedical set to maximise on expanded CHF (congestive heart failure) indication
This article was originally published in Clinica
The market potential for Vasomedical's external counterpulsation (EECP) therapy was boosted this week by around seven-to-ten times, after the US FDA approved a new indication for the device - congestive heart failure (CHF).
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.